Propanc Biopharma, Inc.
Disclosed SEC business address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Propanc Biopharma, Inc. (ticker PPCB, CIK 0001517681) is tracked by Global Barry from its public SEC filings and disclosures. Disclosed industry classification: Pharmaceutical Preparations (SIC 2834). Disclosed business address country: Australia. Every item is grounded on the cited public source — no figures are fabricated.
Full evidence detail
Company deep views this month: 3 of 5.
Filing intelligence
50 filings ingested; deep FILING ANALYSIS shown for 8 filings.
- FACT Only one ingested version of this accession exists; no intra-document revisions have been observed. Change tracking for this filing requires ≥2 ingested versions. 2026-10-05 source ↗
- ANALYSIS This S-1 was filed 80 days after the previous ingested S-1 (2026-07-17). 13 filings of this type are ingested. 2026-10-05 source ↗
- UNKNOWN Changed risk-factor language (Item 1A): not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
- UNKNOWN MD&A highlights: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
- UNKNOWN Material business developments: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
- UNKNOWN Debt / capital-structure changes: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
- UNKNOWN Acquisitions / divestitures: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
- UNKNOWN Litigation / regulatory matters: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-10-05 source ↗
Latest developments
Most recent SEC filing events ingested for this company (newest first).
- FACT S-1 filed 2026-10-05 source ↗
- FACT 10-K filed (period 2026-06-30) 2026-09-25 source ↗
- FACT S-1 filed 2026-07-17 source ↗
- FACT 8-K filed (period 2026-07-08) 2026-07-14 source ↗
- FACT 10-Q filed (period 2026-03-31) 2026-05-14 source ↗
- FACT S-1 filed 2026-04-10 source ↗
- FACT 8-K filed (period 2026-02-20) 2026-02-26 source ↗
- FACT S-1/A filed 2026-02-19 source ↗
- FACT 10-Q filed (period 2025-12-31) 2026-02-17 source ↗
- FACT S-1 filed 2026-02-02 source ↗
Insider ownership filings
No insider ownership filings (Forms 3/4/5) have been ingested for this company. This is not a claim that none exist.
- UNKNOWN No insider ownership filings (Forms 3/4/5) have been ingested for this company. This is not a claim that none exist.
Geographic footprint (disclosed)
Geographic footprint limited to locations disclosed in ingested evidence.
- FACT Principal executive office (disclosed): CAMBERWELL, VICTORIA, C3, 3124
- FACT Mailing address (disclosed): CAMBERWELL, VICTORIA, C3, 3124
- FACT State/country of incorporation (disclosed): DE
Industry classification (disclosed)
Industry classification as disclosed by the issuer's SEC record.
- FACT Primary industry (disclosed SIC): Pharmaceutical Preparations (SIC 2834)
- FACT SEC filer category: Non-accelerated filer<br>Smaller reporting company
Supply chain
No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
- UNKNOWN No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
Risk factors
Risk-factor language requires ingested filing document bodies.
- UNKNOWN Risk-factor language requires ingested filing document bodies.
Sources
- U.S. Securities and Exchange Commission, EDGAR · filing index · retrieved 2026-10-19T23:36:39.266775+00:00
- SEC EDGAR · issuer filing index
Grounded on public SEC filings and disclosures with explicit evidence tiers and citations. This page is informational only and is not investment advice. No figures are fabricated; unavailable data is shown as unavailable.